Big Pharma's China Deal Spree Grows With Latest Tie-Up Worth Up to $7.8 Billion
Western biopharmaceutical companies are increasingly turning to China to source innovation as the industry's looming patent cliff draws closer, according to CNBC.
Written by EGazette’s AI. The facts are drawn from cited sources; the analysis is the AI’s own.
Western biopharmaceutical companies are increasingly striking deals with Chinese drugmakers, with the latest tie-up reported to be worth up to $7.8 billion, according to CNBC.
The deal is part of a broader trend in which Western pharma firms are turning to China to source innovative drug candidates, as the industry faces what has been described as a looming "patent cliff."
The patent cliff refers to a period in which a wave of blockbuster drugs are set to lose patent protection, exposing their manufacturers to generic competition and prompting a search for new revenue-generating treatments.
China's biotech sector has increasingly positioned itself as a source of early-stage drug innovation, attracting licensing and partnership interest from major Western pharmaceutical companies.
Further details on the specific companies involved in the latest deal, and the therapeutic area it covers, were not specified in the available report.
Sources
EGazette summarizes reporting from multiple sources; follow the links for the originals.
Comments
Loading comments…
Related articles
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
Western biopharma companies are increasingly sourcing innovation from China as a wave of patent expirations approaches.
Nike shares fall as retailer posts weak sales, announces layoffs amid restructuring
The company is expected to report another quarter of declining sales as it works to turn around its business, including in China.
Nike announces layoffs amid restructuring as sales decline continues
The sportswear giant is expected to post another quarter of falling sales as it works to turn its business around and revive growth in China.
What went wrong at Nike? How the sportswear giant lost its edge
A series of self-inflicted missteps has weighed on the world's largest sportswear brand in recent years, according to a BBC Business report.
Putin Offers China Partnership on Siberian Copper Deposit
Russian President Vladimir Putin said Chinese companies, among the most active investors in the Russian Far East, could join the development of one of Siberia's largest copper deposits, Kommersant reports.
China's Tang disqualified from Asian Games judo quarter-finals after alleged bite
Tang Jing's opponent's coach claimed their athlete was left with bite marks on her arm during the bout.